Company: PSTV
Filing Date: 2025-06-09
Form Type: DRS
Source: 0000950123-25-005986
Chunk: 25

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-06-09
Form: DRS
Chunk 25
---
 have been approximately $[ ] million, or $[ ] per share. This represents an immediate increase in net tangible book value of $[ ] per share to existing stockholders and an immediate dilution of $[ ] per share to new investors. The table below illustrates this per share dilution:

| Assumed offering price per share                                  
 Historical net tangible book value per share as of March 31, 2025 |     |   | [ | ] |     |   | [ | ] |
|:------------------------------------------------------------------|:----|:--|:--|:--|:----|:--|:--|:--|
| Increase per share attributable to this offering                  |     | $ | [ | ] |     |   |   |   |
| As adjusted net tangible book value per share after this offering |     |   |   |   |     | $ | [ | ] |
| Dilution per share to new investors                               |     |   |   |   |     | $ | [ | ] |

The number of shares of common stock to be outstanding immediately after this offering in the table above is based on [ ] shares outstanding as of [ ], 2025 and excludes, as of [ ], 2025:

| • |     | [ ] shares of common stock issuable upon exercise of stock options outstanding under our equity incentive 
 plans, with a weighted-average exercise price of $[ ] per share;                                          |

| • |     | [ ] shares of common stock reserved for future issuance under our 2015 New Employee Incentive Plan; |

| • |     | [ ] shares of common stock reserved for future issuance under our 2020 Stock Incentive Plan; |

| • |     | [ ] and [ ] shares of common stock issuable upon conversion of [ ] shares of Series B     
 Convertible Preferred Stock and [ ] shares of Series C Preferred Stock, respectively; and |

| • |     | [ ] shares of common stock issuable upon the exercise of warrants to purchase common stock, with a 
 weighted-average exercise price of $[ ] per share.                                                 |

14

Confidential Treatment Requested by Plus Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 THE SELLING STOCKHOLDER This prospectus relates to the possible resale by the selling stockholder, Lincoln Park, of shares of our common stock that